SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ashton, C. H.
Right arrow Articles by Young, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashton, C. H.
Right arrow Articles by Young, A. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

C. H. Ashton

P. B. Moore

P. Gallagher

A. H. Young

Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabisrelieves symptoms of mania and/or depression. The cannabinoids {Delta}9-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or amixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.

Key Words: bipolar disorder • cannabidiol • cannabinoids • cannabis • CBD • depression • dronabinol • mania • nabilone • tetrahydrocannabinol • THC

Journal of Psychopharmacology, Vol. 19, No. 3, 293-300 (2005)
DOI: 10.1177/0269881105051541


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Zuardi, J. Crippa, S. Dursun, S. Morais, J. Vilela, R. Sanches, and J. Hallak
Cannabidiol was ineffective for manic episode of bipolar affective disorder
J Psychopharmacol, January 1, 2010; 24(1): 135 - 137.
[Abstract] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
Z. Atakan
Cannabis use by people with severe mental illness - is it important?
Adv. Psychiatr. Treat., November 1, 2008; 14(6): 423 - 431.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
F. R. Bambico, N. Katz, G. Debonnel, and G. Gobbi
Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex
J. Neurosci., October 24, 2007; 27(43): 11700 - 11711.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Ment. HealthHome page
P. D Skosnik
Cannabis use increases risk of developing symptoms of mania
Evid. Based Ment. Health, May 1, 2007; 10(2): 61 - 61.
[Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
S. M. Strakowski, M. P. DelBello, D. E. Fleck, C. M. Adler, R. M. Anthenelli, P. E. Keck Jr, L. M. Arnold, and J. Amicone
Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania
Arch Gen Psychiatry, January 1, 2007; 64(1): 57 - 64.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
P. J. Zhu and D. M. Lovinger
Ethanol Potentiates GABAergic Synaptic Transmission in a Postsynaptic Neuron/Synaptic Bouton Preparation From Basolateral Amygdala
J Neurophysiol, July 1, 2006; 96(1): 433 - 441.
[Abstract] [Full Text] [PDF]



Advertisement